Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 46

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 1
Chunk 46
---
 and Western Europe in the nine-month period.  Based on the current market conditions, the Company expects a cautious equipment spending environment through the remainder of the year.

The year-over-year increase in core sales in the segment was led by high-single digit increases in core sales in the bioprocessing business in both the three and nine-month periods and was primarily driven by improved consumables demand from large pharmaceutical customers, partially offset by lower year-over-year demand for equipment.  Core sales in the discovery and medical business increased year-over-year as demand for medical and lab filtration consumables more than offset lower demand for protein research equipment in the life science research end-markets.  

Operating Profit Performance

Operating profit margins decreased 400 basis points during the three-month period ended September 26, 2025 as compared to the comparable period of 2024.

Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were unfavorably impacted by:

•Third quarter 2025 impairment charge related to technology and other intangible assets - 475 basis points

Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were favorably impacted by:

•Higher third quarter 2025 core sales and the impact of product mix, net of the impact of changes in leverage from the Company’s operations and administrative cost structure and the impact of currency exchange rates - 75 basis points

31

Operating profit margins increased 110 basis points during the nine-month period ended September 26, 2025 as compared to the comparable period of 2024.

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were favorably impacted by:

•Higher 2025 core sales and the impact of product mix, net of the impact of currency exchange rates - 300 basis points

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were unfavorably impacted by:

•First nine months of 2025 impairment charges related to technology, other intangible assets and a facility - 190 basis points

Amortization of intangible assets as a percentage of sales decreased during both the three and nine-month periods ended September 26, 2025 as compared to the comparable periods of 2024, primarily as a result of the increase in sales.

LIFE SCIENCES

The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic